About this program

IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of T-cell lymphomas.

Cutaneous T-cell lymphomas (CTCL), an orphan disease, is a group of rare cutaneous lymphomas of T lymphocytes with poor prognosis and few therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 85% of certain agressive CTCL subtypes, in particular, Sézary syndrome and transformed mycosis fungoides (tMF). KIR3DL2 has a restricted expression on normal tissues.

IPH4102 was granted orphan drug status in the European Union and in the United States for the treatment of CTCL.

IPH4102 is currently in Phase I trial for the treatment of CTCL.

    Mechanism of action of anti-KIR3DL2

    IPH4102 is currently in a dose escalation and cohort expansion Phase I trial for the treatment of relapsed/refractory CTCL.

    The Phase I trial is an open label and multicenter study. It is performed in Europe (France, Netherlands, United Kingdom) and in the US. Participating institutions include several hospitals with internationally recognized expertise: the Saint-Louis Hospital (Paris, France), the MD Anderson Cancer Center (Houston, Texas), the Stanford University Medical Center (Stanford, CA), the Ohio State University (Columbus, OH), the Leiden University Medical Center (Leiden, Netherlands), and the Guy’s and St Thomas’ Hospital (London, United Kingdom).

    • The dose-escalation part has accrued 25 KIR3DL2-positive CTCL patients in 10 dose levels. The objective was to characterize IPH4102 safety profile, identify the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D); the dose escalation followed an accelerated 3+3 design. Results of the dose-escalation were presented at the EORTC CLTF meeting in October 2017
    • The cohort expansion enrolled 15 patients with Sézary Syndrome and 4 tMF receiving IPH4102 at the RP2D until progression.

    The primary objective of this trial is to evaluate the safety and tolerability of repeated administrations of single agent IPH4102 in this patient population. The secondary objectives include assessment of the drug’s antitumor activity. Clinical endpoints include global objective response rate, response duration and progression-free survival. Exploratory analyses are aimed at identifying biomarkers of clinical activity.

    In a presentation at EORTC CLTF meeting in September 2018 , IPH4102 showed encouraging clinical activity, demonstrated by high response rate and long progression-free survival.